These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28503880)

  • 1. Individualised medicine: why we need Bayesian dosing.
    Donagher J; Martin JH; Barras MA
    Intern Med J; 2017 May; 47(5):593-600. PubMed ID: 28503880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalised dosing of medicines for children.
    Al-Metwali B; Mulla H
    J Pharm Pharmacol; 2017 May; 69(5):514-524. PubMed ID: 28266713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
    Sasaki T; Tabuchi H; Higuchi S; Ieiri I
    Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimens.
    Pitsiu M; Parker EM; Aarons L; Rowland M
    Ther Drug Monit; 2003 Feb; 25(1):36-40. PubMed ID: 12548142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
    Büller HR; Gallus AS; Pillion G; Prins MH; Raskob GE;
    Lancet; 2012 Jan; 379(9811):123-9. PubMed ID: 22130488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool.
    Saffian SM; Duffull SB; Roberts RL; Tait RC; Black L; Lund KA; Thomson AH; Wright DF
    Ther Drug Monit; 2016 Dec; 38(6):677-683. PubMed ID: 27855133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.
    Jelliffe RW; Schumitzky A; Bayard D; Milman M; Van Guilder M; Wang X; Jiang F; Barbaut X; Maire P
    Clin Pharmacokinet; 1998 Jan; 34(1):57-77. PubMed ID: 9474473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomogram for dosing warfarin at steady state.
    Fredriks DA; Coleman RW
    Clin Pharm; 1991 Dec; 10(12):923-7. PubMed ID: 1773579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for Predicting Warfarin Dose Requirements.
    Saffian SM; Wright DF; Roberts RL; Duffull SB
    Ther Drug Monit; 2015 Aug; 37(4):531-8. PubMed ID: 25549208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-source maximum a posteriori-bayesian dosing AdDS to current therapeutic drug monitoring: Adapting to the era of individualized therapy.
    Smith NM; Chan A; Wilkinson LA; Chua HC; Nguyen TD; de Souza H; Shah AP; D'Argenio DZ; Mergenhagen KA
    Pharmacotherapy; 2021 Nov; 41(11):953-963. PubMed ID: 34618919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response.
    Lee C; Coleman RW; Mungall DR
    Clin Pharm; 1987 May; 6(5):406-12. PubMed ID: 3665392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal individualized dosing strategies: A pharmacologic approach to developing dynamic treatment regimens for continuous-valued treatments.
    Rich B; Moodie EE; Stephens DA
    Biom J; 2016 May; 58(3):502-17. PubMed ID: 26537297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
    Enyart JJ; Jones RJ
    Ann Pharmacother; 2005 Jun; 39(6):1002-7. PubMed ID: 15886295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin.
    Garrelts JC; Godley PJ; Horton MW; Karboski JA
    Clin Pharm; 1987 Oct; 6(10):795-9. PubMed ID: 3505841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study.
    Li J; Udy AA; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2012 Jan; 39(1):69-72. PubMed ID: 22024354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Free Open-Source Bayesian Vancomycin Dosing App for Adults: Design and Evaluation Study.
    Oommen T; Thommandram A; Palanica A; Fossat Y
    JMIR Form Res; 2022 Mar; 6(3):e30577. PubMed ID: 35353046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
    Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.